IP Library › Granted Patent US 12,492,377
Granted Patent B2
US 12,492,377 · App. 18/223,338 · Granted Dec 9, 2025

Modified NK-92 haNK003 cells for the clinic

Inventors: Hans Klingemann (Boston, MA); Laurent Boissel (Boston, MA); Patrick Soon-Shiong (Los Angeles, CA)
Assignee: ImmunityBio, Inc.
C12N5/0646A61K40/15A61K40/4205A61K48/00C07K14/55C07K14/70535C12N15/85A61K2239/31A61K2239/38A61K2239/49C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,492,377
App. No.
18/223,338
Granted
Dec 9, 2025
Kind
B2
Abstract

Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.

Claims (19)

1 . A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier, (ii) a medium, and (iii) modified NK-92 cells comprising a polypeptide with at least 90% identity to SEQ ID NO:4 (CD16) and a polypeptide with at least 90% identity to SEQ ID NO:6 (IL-2) and wherein the cells comprise SEQ ID NO:1 on chromosome 17, wherein greater than 90% of the cells in the population of cells express CD56, CD16, CD54, and NKp30 and wherein fewer than 5% of the cells in the population of cells express CD3.

2 . The pharmaceutical composition of claim 1 , wherein the mean doubling time of the cells is between 55 and 70 hours.

3 . The pharmaceutical composition of claim 1 , wherein the population of cells maintains the mean doubling time from 1, 2, 3, 4, 5, 10, 15, 20, or 25 days.

4 . The pharmaceutical composition of claim 1 , wherein the population of cells can be passaged every 1, 2, 3, or 4 days.

5 . The pharmaceutical composition of claim 1 , wherein the cells secrete IL-2 at a concentration of 10 to 60 pg/hour per million cells.

6 . The pharmaceutical composition of claim 1 , wherein the cells are irradiated cells.

7 . The pharmaceutical composition of claim 1 , wherein the cells have reduced downregulation of expression of CD16 compared to a control.

8 . The pharmaceutical composition of claim 1 , wherein the medium is human serum or an equivalent thereof.

9 . The pharmaceutical composition of claim 1 , wherein the medium comprises human serum albumin.

10 . The pharmaceutical composition of claim 1 , wherein the medium comprises human plasma.

11 . The pharmaceutical composition of claim 1 , wherein the medium comprises about 1% to about 15% human serum or human serum equivalent.

12 . The pharmaceutical composition of claim 1 , wherein the medium comprises about 1% to about 10% human serum or human serum equivalent.

13 . The pharmaceutical composition of claim 1 , wherein the medium comprises about 1% to about 5% human serum or human serum equivalent.

14 . The pharmaceutical composition of claim 1 , wherein the medium comprises about 2.5% human serum or human serum equivalent.

15 . The pharmaceutical composition of claim 8 , wherein the serum is human AB serum.

16 . The pharmaceutical composition of claim 1 , wherein the composition comprises an isotonic liquid solution that supports cell viability.

17 . The pharmaceutical composition of claim 1 , wherein the composition further comprises a buffering agent.

18 . A kit comprising the pharmaceutical composition of claim 1 and instructions for use.

19 . The kit of claim 18 , wherein the kit further comprises an antibody.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2023
From: KLINGEMANN, HANS; BOISSEL, LAURENT; SOON-SHIONG, PATRICK
To: NANTKWEST, INC.
Reel/Frame 065501/0458 →
CHANGE OF NAME Recorded Nov 8, 2023
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 065524/0063 →
Continuity (5)
Continuation 16937370 · Jul 23, 2020
Continuation 16424201 · May 28, 2019
Division 15914665 · Mar 7, 2018
Provisional Application 62468890 · Mar 8, 2017
Related Publication 20240010979A1 · Jan 11, 2024
References Cited (42)
US 6030833A · Seebach · 2000 [cited by examiner]
US 7029671B1 · Koezuka · 2006 [cited by examiner]
US 7618817B2 · Campbell · 2009 [cited by examiner]
US 8034332B2 · Klingemann · 2011 [cited by applicant]
US 8313943B2 · Campbell · 2012 [cited by applicant]
US 10138462B2 · Kilingemann · 2018 [cited by applicant]
US 10456420B2 · Lee · 2019 [cited by applicant]
US 20020068044A1 · Klingemann · 2002 [cited by applicant]
US 20040052770A1 · Klingemann · 2004 [cited by applicant]
US 20060292156A1 · Campbell · 2006 [cited by applicant]
US 20180193383A1 · Lee · 2018 [cited by applicant]
CA 2289915A1 · 1998 [cited by applicant]
EP 2161339A1 · 2010 [cited by applicant]
WO 9849268A1 · 1998 [cited by applicant]
WO 2016160602A2 · 2016 [cited by applicant]
WO 2016201304A1 · 2016 [cited by applicant]
Konstantinidis et al. Experimental Hematology 33(2):159-164, 2005 (Year: 2005). [cited by examiner]
Korean Patent Application No. 10-2024-7001475, “Notice of Preliminary Rejection,” dated Mar. 13, 2024, 5 pages. [cited by applicant]
Israel Patent Application No. 268617 “Office Action,” dated Feb. 5, 2023, 3 pages. [cited by applicant]
Faibish et al., “A YKL-40 neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers,” Mol Cancer Ther., May 2011, 10(5): 742-751. [cited by applicant]
Gong et al., “Characterization of a Human Cell Line (NK-92) with Phenotypical and Functional Characteristics of Activated Natural Killer Cells,” Leukemia, Apr. 1994, vol. 8., No. 4, pp. 652-658. [cited by applicant]
International Application No. PCT/US2018/021332, International Search Report mailed Jun. 8, 2018, 5 pages. [cited by applicant]
Jing et al., “Identification of an ADAM17 Cleavage Region in Human CD16 (FcγRIII) and the Engineering of a Non-Cleavable Version of the Receptor in NK Cells,” Mar. 27, 2015, PLOS ONE | DOI:10.1371/journal.pone.0121788. [cited by applicant]
Jochems et al., “An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele,” Oncotarget, 2016, vol. 7, (No. 52), 86359-86373. [cited by applicant]
Klingemann et al., “Natural Killer Cells for Immunotherapy—Advantages of the NK-92 Cell Line over Blood NK Cells,” Frontiers in Immunology, Mar. 2016, vol. 7, Article 91, 7 pages. [cited by applicant]
Tsang et al., Journal for Immuno Therapy of Cancer (2016) vol. 4, Supp. Supplement 1, Abstract No. P20, Meeting Info: 31 [cited by applicant]
Boissel et al., Cancer Researh (2016) vol. 76, No. 14, Supp. Supplement, Abstract No. 2302, Meeting Info: 107 [cited by applicant]
PCT/US2018/021332 , “International Preliminary Report on Patentability”, Sep. 19, 2019, 8 pages. [cited by applicant]
European Application No. 18763512.3, Extended European Search Report, mailed Dec. 1, 2020, 8 pages. [cited by applicant]
Carlsten, et al., “Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications,” Frontiers in Immunology, vol. 6, Jun. 2015, 9 pages. [cited by applicant]
Maki, et al., “Factors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92,” Journal of Hematotherapy and Stem Cell Research, vol. 10, No. 3, Jun. 2001, pp. 369-383. [cited by applicant]
Canadian Application No. 3,053,252, First Examiner's Report, dated Apr. 7, 2021, 3 pages. [cited by applicant]
Australian Patent Application No. 2018231193, First Examination Report, dated May 25, 2021, 4 pages. [cited by applicant]
Australian Patent Application No. 2021236511, First Examination Report, dated Oct. 29, 2021, 4 pages. [cited by applicant]
Australian Patent Application No. 2021236511, Second Examination Report, dated Nov. 11, 2021, 2 pages. [cited by applicant]
Australian Paent Application No. 2021236511, Acceptance Fee Official Receipt, dated Dec. 12, 2021, 1 page. [cited by applicant]
Notice of Reasons for Rejection, Japanese Patent Application No. 2019-548664, dated Jan. 17, 2022, 7 pages. [cited by applicant]
Korean Patent Application No. 10-2019-7028804, “Notice of Preliminary Rejection,” dated Sep. 7, 2022, 7 pages. [cited by applicant]
Israel Patent Application No. 268617, Office Action, dated Oct. 30, 2022, 7 pages. [cited by applicant]
Chinese Patent Application No. 201880016940.6, Office Action, dated Aug. 22, 2022, 19 pages. [cited by applicant]
Rezvani and Rouce, “The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer,” Frontiers in Immunology, Nov. 2015, vol. 6, Article 578, 13 pages. [cited by applicant]
European Patent Application No. 18763512.3, “Examination Report,” dated Oct. 2, 2024, 4 pages. [cited by applicant]